196 related articles for article (PubMed ID: 32240364)
21. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
22. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
[TBL] [Abstract][Full Text] [Related]
23. Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer.
Momesso DP; Vaisman F; Caminha LS; Pessoa CH; Corbo R; Vaisman M
J Endocrinol Invest; 2014 Jan; 37(1):57-64. PubMed ID: 24464451
[TBL] [Abstract][Full Text] [Related]
24. Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system.
Markantes GK; Karakioulaki M; Papanikolopoulou S; Theodoropoulou A; Markou KB; Vagenakis AG; Spyridonidis T; Goulis DG; Michalaki MA
Hormones (Athens); 2021 Dec; 20(4):761-768. PubMed ID: 34383288
[TBL] [Abstract][Full Text] [Related]
25. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
[No Abstract] [Full Text] [Related]
26. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
27. Patient Perspectives on the Extent of Surgery and Radioactive Iodine Treatment for Low-Risk Differentiated Thyroid Cancer.
Lubitz CC; Kiernan CM; Toumi A; Zhan T; Roth MY; Sosa JA; Tuttle RM; Grubbs EG
Endocr Pract; 2021 May; 27(5):383-389. PubMed ID: 33840638
[TBL] [Abstract][Full Text] [Related]
28. Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment.
Yi W; Kim BH; Kim M; Ryang SR; Jang MH; Kim JM; Kim EH; Jeon YK; Kim SS; Kim IJ
Endocr J; 2020 Dec; 67(12):1193-1198. PubMed ID: 32727965
[TBL] [Abstract][Full Text] [Related]
29. Optimal Timing of Initiating Dynamic Risk Stratification During the Early Postoperative Period in Patients with Differentiated Thyroid Carcinoma After Thyroidectomy and Radioactive Iodine Remnant Ablation.
Park JH; Moon GS; Nam KT; Yoon JH
Ann Surg Oncol; 2021 Oct; 28(11):6580-6589. PubMed ID: 33677764
[TBL] [Abstract][Full Text] [Related]
30. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
[TBL] [Abstract][Full Text] [Related]
31. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
32. Low iodine diet in differentiated thyroid cancer: a review.
Li JH; He ZH; Bansal V; Hennessey JV
Clin Endocrinol (Oxf); 2016 Jan; 84(1):3-12. PubMed ID: 26118628
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant Radioactive iodine 131 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience [corrected].
Al-Qahtani KH; Al Asiri M; Tunio MA; Aljohani NJ; Bayoumi Y; Fatani H; AlHadab A
J Otolaryngol Head Neck Surg; 2015 Dec; 44():51. PubMed ID: 26621255
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy.
Súss SKA; Mesa CO; Carvalho GA; Miasaki FY; Chaves CP; Fuser DC; Corbo R; Momesso D; Bulzico DA; Graf H; Vaisman F
Arch Endocrinol Metab; 2018; 62(2):149-156. PubMed ID: 29641738
[TBL] [Abstract][Full Text] [Related]
35. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
36. Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation.
Hong CM; Lee WK; Jeong SY; Lee SW; Ahn BC; Lee J
Nucl Med Commun; 2014 Nov; 35(11):1119-26. PubMed ID: 25144561
[TBL] [Abstract][Full Text] [Related]
37. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
38. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
[TBL] [Abstract][Full Text] [Related]
39. Acknowledging gray areas: 2015 vs. 2009 American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients.
Frangos S; Iakovou IP; Marlowe RJ; Eftychiou N; Patsali L; Vanezi A; Savva A; Mpalaris V; Giannoula EI
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):185-189. PubMed ID: 27557846
[TBL] [Abstract][Full Text] [Related]
40. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]